Paradigm Biocapital Advisors LP Zai Lab LTD Transaction History

Paradigm Biocapital Advisors LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$22.97 - $30.58 $1.16 Million - $1.55 Million	-50,604 Reduced 4.43%	1,091,779 $29.8 Million
Q3 2023 Nov 14, 2023	BUY	$22.72 - $31.49 $6.3 Million - $8.73 Million	277,086 Added 32.02%	1,142,383 $27.8 Million
Q2 2023 Aug 14, 2023	BUY	$25.3 - $39.67 $2.14 Million - $3.36 Million	84,739 Added 10.86%	865,297 $24 Million
Q1 2023 May 15, 2023	BUY	$30.21 - $48.1 $8.01 Million - $12.8 Million	265,284 Added 51.48%	780,558 $26 Million
Q4 2022 Feb 14, 2023	BUY	$22.28 - $38.71 $11.5 Million - $19.9 Million	515,274 New	515,274 $15.8 Million

124

49.5M

223K

588K

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $2.68B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

Get notified when there are updates to the investment portfolio of Paradigm Biocapital Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Paradigm Biocapital Advisors LP with notifications on news.